SCHEMBL3765360

SCHEMBL3765360

O=C(N1CCCC1)N(O)c1cc[c]cc1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.41
ALDH1A1 P00352 4/20 0.41
POLB P06746 3/20 0.41
HPGD P15428 6/20 0.37
GAA P10253 3/20 0.35
P2RX4 Q99571 3/20 0.33
P2RX1 P51575 2/20 0.33
P2RX3 P56373 2/20 0.33
KMT2A Q03164 3/20 0.33
MEN1 O00255 2/20 0.33
MAPT P10636 2/20 0.33
BCHE P06276 1/20 0.33
HTT P42858 1/20 0.33
LMNA P02545 2/20 0.33
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32
NPSR1 Q6W5P4 2/20 0.32
KDM4E B2RXH2 1/20 0.32
MAPK1 P28482 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16161817 0.81 ALDH1A1 (0.44) SMN1; SMN2ALDH1A1POLBHPGDGAA
SCHEMBL3759117 0.78 ALDH1A1 (0.69) SMN1; SMN2ALDH1A1POLBHPGDGAA
SCHEMBL3765356 0.71 SMN1; SMN2 (0.42) SMN1; SMN2ALDH1A1POLBHPGDGAA
SCHEMBL3763750 0.70 MAPT (0.38) SMN1; SMN2ALDH1A1POLBHPGDKMT2A
SCHEMBL161104 0.69 HPGD (0.69) ALDH1A1HPGDKMT2AMEN1MAPT
SCHEMBL8290239 0.69 ALDH1A1 (0.40) SMN1; SMN2ALDH1A1POLBMAPT
SCHEMBL3760367 0.69 MEN1 (0.36) SMN1; SMN2ALDH1A1HPGDKMT2AMEN1
SCHEMBL7641419 0.69 RAB9A (0.32) ALDH1A1HPGDGAARAB9AKDM4E
SCHEMBL20197 0.68 HPGD (0.73) ALDH1A1HPGDKMT2AMEN1MAPT
SCHEMBL27978775 0.68 HPGD (0.73) ALDH1A1HPGDKMT2AMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2029570-B1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2014-10-15 EP disclosed
US-8324204-B2 Fused thiophene derivatives as kinase inhibitors UCB PHARMA SA (BE) 2012-12-04 US disclosed
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-12-02 US disclosed
WO-2009122148-A1 FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS PI3K KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-10-08 WO disclosed
WO-2009071890-A1 TRICYCLIC KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
WO-2009071895-A1 FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
EP-2029570-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB Pharma S.A. (BE) 2009-03-04 EP disclosed
WO-2007141504-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2007-12-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors PIKFYVE, PI4KA, PIK3CA SMN1; SMN2 1864/4885ALDH1A1 3061/4885POLB 2137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.